• 대한한방부인과학회지
• /
• 제31권3호
• /
• pp.109-120
• /
• 2018

Objectives: The purpose of this study is to report the effect of Korean medicine treatments on a chronic pelvic inflammatory disease (CPID). Methods: We treated 2 cases of chronic pelvic inflammatory disease patients with Korean herbal medicine, acupuncture and moxibustion. One patient is a 50 years old woman, who suffered from uterine bleeding, lower abdominal pain, right pelvic pain. She was treated with Gwichuligyeong-tang-gami and Samul-tang-gami. Other patient is a 40 year old woman, who appealed for pain such as pelvic pain, lower abdominal pain, urinary frequancy, dysuria. She was treated with Cheongpochugeo-tang. Both patients are taken acupuncture at Junggeuk (CV3), Gwanwon (CV4), Chagung (CA111), Sameumgyo (SP6), Eumneungcheon (SP9) and moxified at Gwanwon (CV4). Results: After treatments, their symptoms were remarkably improved. Conclusions: This study suggests that Korean medicine treatments have significant effect on reducing symptoms of chronic pelvic inflammatory disease.

• 대한한방부인과학회지
• /
• 제36권3호
• /
• pp.78-94
• /
• 2023

Objectives: The purpose of this study is to review the trends of clinical trials of traditional herbal medicine Gyejibongnyeong-hwan for chronic pelvic inflammatory disease in CNKI. Methods: We searched relevant studies using Chinese National Knowledge Infrastructure (CNKI). Data retrieval was carried out by December 20^th, 2021. We analyzed characteristics of study subjects, treatment period, composition of prescription, outcome and adverse event of selected studies and the risk of bias was assessed by using Cochrane's risk of bias tool. Results: Among the total 988 studies, 10 studies met the inclusion criteria. All of the studies were randomized controlled studies and written in Chinese. In all studies, Gyejibongnyeong-hwan was effective in improving chronic pelvic inflammatory disease. Conclusions: This study suggests that Gyejibongnyeong-hwan can be effective in treating chronic pelvic inflammatory disease compared to antibiotics treatment. Further large and well-established randomized placebo controlled trials will be needed.